ITGA4: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of ITGA4. The page also collects GeneMedi's different modalities and formats products for ITGA4 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the ITGA4 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
The gene encodes a member of the integrin alpha chain family of proteins. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain that function in cell surface adhesion and signaling. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha 4 subunit. This subunit associates with a beta 1 or beta 7 subunit to form an integrin that may play a role in cell motility and migration. This integrin is a therapeutic target for the treatment of multiple sclerosis, Crohn's disease and inflammatory bowel disease. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2015]
|Gene Official Name||ITGA4|
|Gene Alias||CD49D, IA4|
|Protein Sub-location||Transmembrane Protein|
|Category||Therapeutics Target, INN Index, Immuno-oncology Target|
Pre-made ITGA4-specific INN-index biosimilar (antibody&conjugates)-Vedolizumab, Etrolizumab, Abrilumab, Natalizumab
Anti-ITGA4 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
|Cat No.||Products Name (INN Index)||INN Name||Previous Name||Target||Format||Order|
|GMP-Bios-ab-616||Pre-Made Vedolizumab biosimilar, Whole mAb, Anti-ITGA4;ITGB7 Antibody: Anti-CD49D/IA4 therapeutic antibody||Vedolizumab||ITGA4;ITGB7||Whole mAb|
|GMP-Bios-ab-200||Pre-Made Etrolizumab biosimilar, Whole Mab: Anti-ITGA4;ITGB7;ITGAE;ITGB7 therapeutic antibody||Etrolizumab||ITGA4;ITGB7;ITGAE;ITGB7||Whole mAb|
|GMP-Bios-ab-005||Pre-Made Abrilumab biosimilar, Whole mAb, Anti-α4β7/Integrin alpha 4 beta 7 Antibody: Anti-LPAM‑1 therapeutic antibody||Abrilumab||α4β7/Integrin alpha 4 beta 7||Whole mAb|
|GMP-Bios-ab-367||Pre-Made Natalizumab biosimilar, Whole mAb, Anti-ITGA4 Antibody: Anti-CD49D/IA4 therapeutic antibody||Natalizumab||ITGA4||Whole mAb|
Pre-made anti-ITGA4 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-ITGA4 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-ITGA4 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Cat No.||Antibody Name||Format||Classified by tag||Order|
|GM-Tg-hg-T97587-Ab||Anti-ITGA4 monoclonal antibody||mab||Biofunctional antibody, Therapeutics Target antibody|